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ABSTRACT
Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-negative bacteria. In 
animals, intraperitoneal administration of LPS, stimulates innate immunity and the production of pro-
inflammatory cytokines. LPS provides an inflammatory stimulus that activates the neuroimmune and 
neuroendocrine systems resulting in a set of responses termed sickness behavior. The purpose of this 
protocol is to describe step-by-step the preparation and procedure of application of intraperitoneal 
injection of LPS in rats, as a guide for those researchers that want to use this assay to mount an 
inflammatory response. LPS intraperitoneal challenge in rats has been widely used to evaluate anti-
inflammatory reagents and to address basic scientific questions.
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RESUMEN
El lipopolisacárido (LPS) es un componente de la membrana externa de las bacterias Gram 
negativas. En animales, la administración intraperitoneal de LPS estimula la inmunidad innata y la 
producción de citoquinas proinflamatorias. El LPS proporciona un estímulo inflamatorio que activa 
el sistema neuroinmunológico y el sistema neuroendocrino, lo que da como resultado un conjunto 
de respuestas denominadas conductas de enfermedad. El propósito de este protocolo es describir 
paso a paso la preparación y el procedimiento de aplicación de la inyección intraperitoneal de LPS en 
ratas, como una guía para aquellos investigadores que desean utilizar este método para estimular una 
respuesta inflamatoria en el animal. La estimulación con LPS en ratas, aplicada intraperitonealmente, 
se ha utilizado ampliamente para evaluar reactivos antiinflamatorios y para abordar preguntas básicas 
de investigación científica.
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INTRODUCTION
Lipopolysaccharide (LPS) is a component 
of the outer membrane of Gram-negative bacteria 
and its major virulence factor (Figure 1 A, B). It 
is a potent endotoxin that provides a persistent 
inflammatory stimulus (1). Systemic administration 
of LPS, even at low doses, induces the production 
of pro-inflammatory cytokines that activate the 
neuroimmune and neuroendocrine systems, resulting 
in sickness behavior (2). Specifically in rats, the 
acute administration of LPS induces symptoms of 
depression such as anhedonia, diminished cognitive 
function, retarded motor activity, reduction in 
exploration, decreased social interaction, fever, 
hypersomnia, activation of the hypothalamic-
pituitary-adrenal axis, and increased sympathetic 
activation (3-6). 
It has been shown that acute administration 
of LPS, disrupts the consolidation of memory 
processes. For example, if it is administered acutely, 
prior to training, it impairs cue-fear conditioning, 
whereas chronic administration of LPS, has been 
found to impair spatial memory and promote 
memory and learning deficits (7-9). A single 
intraperitoneal injection of LPS in a dose of 100 
micrograms per kilogram in adult male Wistar rats, 
impaired memory object recognition (10). Shaw et 
al., 2005, reported that a single intraperitoneal 
injection of LPS in a dose of 250 micrograms per 
kilogram impaired hippocampal dependent spatial 
learning in the Morris water maze behavioral test. 
In another study, in adult male Wistar rats, a single 
injection of LPS in a dose of 1mg/kg, impaired 
cognitive performance in the Barnes Maze test and 
in the inhibitory avoidance test (12).  
Peripheral administration of LPS, emulates a 
systemic infection, therefore this immune challenge 
has been widely used to increase neuroinflammatory 
signaling. In addition, LPS is used as a tool to activate 
microglia and cells of the peripheral immune 
system (13). It has been shown that peripheral 
administration of LPS induces the activation of 
microglia throughout the brain (14). This activation 
manifests itself in a matter of hours, observing 
a peak from 8 to 24 hours, depending on the 
concentration applied of the endotoxin (14). 
LPS binds CD14 on microglia membranes 
forming the complex LPS-CD14 which then interacts 
with the Toll-like-receptor - (TLR-) 4 (15,16) (Figure 
1 C ). TLR-4 activates microglia by initiating signal 
transduction cascades to produce an early synthesis 
of pro-inflammatory cytokines in the brain, such as 
interleukin (IL) -1ß, IL-6 and tumor necrosis factor 
alpha (TNF-α), IL-12, IL-17A, IL-18, inducible 
nitric oxide synthase (17-19); chemokines such 
as CCL2, CCL5, and CXCL8; complement system 
proteins; and anti-inflammatory cytokines such as 
IL-10 and transforming growth factor- ß (TGF-ß) 
(20-22). 
Cytokines are key modulators of the immune 
response and if pro-inflammatory cytokines 
are present chronically in the central nervous 
system, it can cause dyshomeostasis (23). A 
sustained release of pro-inflammatory mediators 
by the activation of microglia, enhances oxidative 
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stress and nitrosative stress that can perpetuate 
neuroinflammation, and may be the cause of 
neurodegenerative diseases (24). 
LPS has become a very popular substance 
to investigate the responses of glial cells to 
neuroinflammatory stimuli, simulating the neuronal 
environment in different disorders of the central 
nervous system (25). For example, LPS-induced 
systemic inflammation has been used worldwide in 
experimental in vivo models of neurodegenerative 
diseases such as Alzheimer’s disease (8, 26, 27), 
Parkinson disease (28,29), Amyotrophic Lateral 
Sclerosis (30), and Multiple Sclerosis (31). The 
LPS-induced animal model for these specific 
diseases, have been used to study the pathologies’ 
mechanisms as well as to test therapeutic agents. 
Challenge of LPS in rats can also be used 
as a model to study the pathophysiology of 
depression, since it has long been hypothesized 
that clinical depression may be a consequence of 
a dysregulated immune system with an increased 
production of pro-inflammatory cytokines, such as 
IL-1 ß, IL-6. And TNF-α (32-35). LPS administration 
to healthy study participants, caused an increase 
of these pro-inflammatory cytokines in circulation, 
accompanied by an elevation in serum cortisol 
levels and increased negative emotions such as 
sadness, anxiety, and depressed mood, all of 
these symptoms of major depression (36-41). In 
the same way, systemic LPS injection to animals 
causes effects comparable to those found in 
humans (42).
Investigations in rodents, using from low 
to high doses of LPS, induce “depressive-like” 
behavior and produce an effect on neuroendocrine 
and inflammatory pathways. For example, after 24 
hours post-intraperitoneal injection, LPS (1 μg/kg 
to 250 μg/kg), significantly reduced body weight, 
increased corticotrophin hormone (ACTH) (doses 
ranging from 15 μg/kg to 250 μg/kg) and serum 
corticosterone levels (doses ranging from 5 μg/kg 
to 250 μg/kg) (Bison et al., 2009). In addition, LPS 
raised serum interleukins, specifically IL-1ß and 
IL-6 (doses ranging from 5 μg/kg 250 μg/kg) and 
TNF-α (doses ranging from 1 μg/kg 250 μg/kg). 
Social interaction and preference for saccharin 
were significantly decreased at all doses of LPS 
tested (1 to 250 μg/kg) while a robust reduction in 
home-cage activity was observed starting at 15 μg/
kg (42). Accordingly, studies have demonstrated 
that peripheral administration of LPS depresses 
social exploration and locomotor activity as well 
(43-47). The behavioral effects caused by LPS 
challenge at different doses tested, are associated 
with the stimulation of the hypothalamic-pituitary-
adrenal axis and the immune system. Even at 
very low doses LPS can stimulate the immune 
system and cause behavioral alterations in 
rats. The LPS challenge provides a preclinical 
model for investigating potential therapeutics for 
inflammatory associated mood disorders.
Possible interactions between stress and 
immune-inflammatory pathways in the pathogenesis 
of depression have been proposed, and the LPS 
systemic challenge combined with stress paradigms, 
may address these pathways. For instance, when 
combined with a low dose of LPS challenge 
(0.1mg/kg to 0.5 mg/kg), chronic stress in 
rodents, exacerbate depressive-like behavior (48). 
The combination of stress with LPS elevated IL-1 
ß levels in the brain (48). Repeated challenges of 
LPS when combined with chronic mild stress can 
induce as well, increases in plasma corticosterone 
and TNF-α in rats (49).
Inflammation is a pathogenic pathway to 
neuropsychiatric disorders, but also in a wide range of 
diseases including rheumatoid arthritis (50), Chron’s 
disease (CD) (51), and cardiovascular disease (52), 
among others. The LPS peripheral challenge offers 
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researchers an experimental model to investigate 
specific targets of inflammatory pathways and 
responses under controlled conditions. 
Rheumatoid arthritis is a chronic 
inflammatory autoimmune disease characterized 
by extensive synovitis resulting in erosions of 
marginal bone and articular cartilage that may lead 
to joint destruction (50). A popular experimental 
model of autoimmune arthritis is achieved by 
intraperitoneal immunization with type II collagen 
(CII) emulsified with complete Freund’s adjuvant 
(mineral oil, and heat- killed mycobacteria) and 
LPS (53). This model results in signs of arthritis 
seen in humans, including joint inflammation. 
Histologically, an intense infiltration of inflammatory 
cells is seen, and anti-CII immunoglobulin G (IgG) 
and IgG2a antibodies are markedly produced. Also, 
secretion of cytokines, including interleukins-12 
and-1ß, interferon-Y and TNF-α, is observed in 
rodents that receive this challenge compared to 
controls (53).
CD is a chronic inflammatory bowel 
disease characterized by mucosal ulceration and 
inflammation, and commonly affects the distal 
small intestine (51). Nonetheless, it can also 
occur anywhere among the gastrointestinal tract. 
The main factors that provoke the onset of this 
immune mediated condition are genetics, gut 
immune response, the microbiota, and triggering 
factors. LPS has been detected in the plasma 
of patients with CD, and an abnormal microflora 
and/or an increased permeability of the intestinal 
mucosa have been identified as cofactors causing 
endotoxemia (54). Phagocytosis and killing exerted 
by polymorphonuclear cells and monocytes and 
the T-cell dependent antibacterial activity are 
decreased in CD patients. This may also explain 
the origin of LPS in these diseases (54).
Clinical and epidemiological studies have 
demonstrated a strong link between markers of 
inflammation and risk of future cardiovascular 
disease (52). Inflammation in the vasculature may be 
a response to infectious agents.  LPS, as an infective 
agent, activates the innate immune response cells 
with a plethoric production of cytotoxic mediators. 
Cardiac myocytes are cells that also express TLR-4, 
and are susceptible to direct damage by LPS. It has 
been reported, low levels of LPS depress cardiac 
myocyte contractility, weakens the response of the 
beta-adrenergic system, and induces cell death by 
apoptosis (55-56). 
Since the LPS challenge can also be used 
to study sepsis in high doses, a dosing regimen 
is suggested that triggers a mild inflammatory 
response. Consulting the vast amount of literature 
is recommended to provide important information 
regarding the dose to be used depending on 
the effects that will be measured with the LPS 
challenge. It is also important to keep in mind the 
effects produced by LPS immune challenge depend 
on genetic background (strain) of the animal (58). 
Also, systemic administration of LPS induces 
time-dependent behavioral alterations in rodents, 
which are related to either sickness behavior or 
depression. Short term-behavioral alterations 
are related to sickness behavior during the peak 
secretion of cytokines, and long-term, are related 
to the pathophysiology linked to depression (59).
The main objective of this protocol is to 
provide a guide to researchers, and describe 
step-by step on how to prepare a solution of 
LPS on saline vehicle, and how to manipulate a 
rat when placing an intraperitoneal injection. As 
stated before, the dose of LPS depends on the 
variables and outcomes that will be measured in 
each experiment performed. This protocol follows 
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guidelines for acceptable injection volumes in rats. 
The procedure must be done by trained persons 







• One vial to store saline solution or an Eppendorf 
tube. The size will depend on the amount of LPS 
solution that will be prepared and the quantity of 
saline solution to be stored.
• A multi-dose amber or opaque vial to store LPS.
• Weighing boat.
• Weighing spoon or spatula.
• Magnetic stirring bar.
• (N) 1 milliliter volume syringes (N stands for the 
quantity of rats to be injected).
• (N) 23-25 gauge X 1 inch hypodermic needles 
(N stands for the quantity of rats to be injected).
• Small towel or piece of cloth to cover half of 
the animal’s body at the time of injection (if it is 
applied by one person).
• Sharps bin to dispose used needles.
• Sterile gauze pads.
CHEMICAL REAGENTS
• Sterile saline solution containing 0.9% sodium 
chloride (NaCl) in water.
• Ethanol (70%) to disinfect the cap of the vials.
BIOLOGICAL REAGENTS
• Lipopolysaccharide from Escherichia coli 0127: 
B8 (Sigma, code: L3129).
• Rats of any age according to the aims of the project 
(Sprague Dawley, Wistar or any other strain).
HUMAN RESOURCES




Important:  Before starting the execution of 
any procedure, read this section and the following 
one (Considerations) completely, evacuate doubts 
and make sure you have understood all the 
necessary information.
LPS PREPARATION 
The best thing to do would be to prepare it 
on the same day that it is going to be injected. 
However, under minimal conditions (that is, 
they are not the most desired, but are acceptable), 
you can work with LPS from previous days 
(especially if it was a left over), as long as it has 
been kept in refrigeration (2-8°C) and shake very 
well before using it. This is the recommendation 
given by the commercial provider.
• To prepare a dose of 0.5 milligrams (mg) per 
kilogram (kg) of weight of the rat and obtain an 
injection volume of 0.5 milliliters (ml) per kg of 
weight, calculate the mass of reagent and the 
Optimal Minimum
Person Tasks Person
A Weighing of the animals to be injected, 
preparation of  saline solution and  LPS 
solution
A
B Transport of rats from the vivarium to the 
laboratory  or room where the injection is 
made and returned to the vivarium
C Intraperitoneal injection of the animal
3 Total people required according to 
condition:
   ←Optimal                    Minimum→
1
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total volume of solution for injection to prepare, 
taking into account the total weight of the rats 
(see Table 2). Note in Table 2 that a mass in 
excess of the LPS is always weighed in order 
to prepare a surplus of the solution, foreseeing 
that there may be volume loss in the walls of the 
syringes and/or needles ("dead volume" ).
Table 2. Data to calculate the amount of reagents 
that must be prepared.
• Once the amount of LPS to prepare has been 
calculated, start the mass measurement. Since 
very small masses will normally be measured, 
the best measure is the mass difference, using 
at once the container that will contain the final 
solution (thus avoiding loss of reagent during 
transfer from one container to another). To do 
this, open one of the side gates of the analytical 
balance and place in the center of the plate the 
opaque vial in which the LPS will be prepared 
and close all the gates of the weighing chamber. 
Use the tare function ("Tare" or "0" button) to 
return the balance reading to zero with the mass 
of the vial included.
• Once the reading of the scale indicates 0.0 
mg, take the amount of milligrams of LPS to be 
diluted (Value C, Table 2) in saline solution with 
the stainless steel spoon spatula and place them 
in the vial.
• Remove the vial from the weighing chamber of the 
balance, close the gates, tare the balance again 
and, once it has returned to 0.0 mg, turn it off.
• To the mass of reagent measured in the vial, add 
the volume of corresponding saline solution to 
reach a solution of concentration 1 mg LPS / mL 
(Value D, Table 2). This is to inject 0.5 mL per kg 
of the weight of the rat with this dose (0.5 mg 
LPS / kg). For example, if you calculate that the 
total weight of the rats to be injected is 2545 
grams (g), dilute 2545 mg of LPS in 2545 mL 
of saline.
• Once the saline solution is added, introduce the 
agitation tablet and place the vial in the magnetic 
stirrer for 15 minutes at medium speed to mix 
the solution well.
• If the LPS solution is not to be used immediately, 
store the refrigerator at 4 degrees Celsius.
• When it is to be used, remove from the refrigerator 
and shake on the vortex shaker for 30 seconds 
before placing the injections (or on a magnetic 
stirrer for 1 minute, if the magnetic stirring bar 
has not been removed).
• If it has been more than 24 hours since it 
was placed in the refrigerator (check storage 
conditions in Table 3) and it is going to be used 
to inject the rats, it is advisable to put it back in 
the magnetic stirrer for 15 minutes since it is 
normal for the solution to sediment.
INTRAPERITONEAL INJECTION OF LPS 
• Disinfect the lid of the multiple dose vial with 
gauze and 70% ethanol.
• Determine the amount of volume per rat to be 
injected from the LPS solution.
• Raise the plunger of the syringe to be used to fill 
the syringe to the amount of LPS solution that 
will be administered to the rat. In this step it is 
recommended to place the bevel of the needle up 
and that the syringe be positioned in such a way 
that we can read the numbering of the syringe.
• With care and delicacy the animal is removed 
from its cage and its movement is restricted 
appropriately, the head of the animal is positioned 
towards the floor. A small towel or piece of cloth 
is placed to cover the animal from the head to 
the middle of its body. It should not be too tight. 
Rotate the animal and place the head and back 
Value A Value B Value C Value D
Total mass of 
animals (kg)
Minimum 
mass of LPS 
required (mg)
Mass of 





to dissolve the 
LPS (mL)




[Value C / 1 
mg/mL] =
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of the body on the arm and elbow on the arm 
with less force. This arm will help to immobilize 
the animal. The tail is placed between the thumb 
and ring fingers of that same hand. With the 
other hand inject.
• Identify the anatomical points of the rat to inject 
into the appropriate area of the abdomen.
• Generally, the site to be injected into the animal is 
the lower right quadrant of the abdomen to avoid 
damaging the surrounding abdominal organs, 
the urinary bladder and the cecum which is the 
first portion of the large intestine. If you are going 
to inject for several days you can alternate the 
injection site to the lower left quadrant of the 
abdomen (Figure 2).
• Insert the needle with the bevel of the needle 
facing up into the lower quadrant of the abdomen 
at an angle of 30-40 degrees. Insert the needle 
until the entire bevel enters the abdominal 
cavity. In middle-aged and elderly rats it is 
necessary to insert almost the entire length of 
the needle since these animals have more fat in 
that abdominal area than the young.
• You should pull the plunger before placing the 
injection to ensure negative pressure, if any, 
proceed with the injection.
• Push the plunger until the entire solution is 
administered. This can last from one to two seconds.
• Once the solution is administered, place the 
animal back into the cage.
• Remove the needle from the syringe and discard 
the syringe in the sharps bin and discard the 
syringe in the normal trash. If the syringe 
becomes contaminated with fluids from the rat, 
it should be discarded in a  biohazard waste 
disposable bag.
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CONSIDERATIONS
Table 3. Critical points in the protocol, justification and care to ensure adequate execution.
Critical Points Why is it a critical point? Related care
Storage of the LPS solution Once prepared, the LPS solution can only 
be stored for a certain time and under 
certain conditions to ensure its integrity at 
the time of injection.
To ensure the stability of the LPS solution, use the 
following storage conditions, depending on the supplier 
of the reagent (Sigma):
• Cooling (2-8 ° C): stability up to 1 month.
• Freezing (-20 ° C): stability up to 2 years (store in 
aliquots to avoid repeated freeze / thaw cycles).
Rat injection When injecting the LPS solution, care must 
be taken so that the needle does not move 
inside the abdomen, to avoid lacerating 
surrounding organs or blood vessels.
Avoid causing harm to the animal:
• Carrying out a good immobilization of it.
• Making sure to puncture with the needle at the 
anatomical site indicated.
When injecting, if a green solution is 
aspirated, it may be a sign that the 
intestine has been penetrated, if a yellow 
liquid comes out it may indicate that 
the bladder was punctured, and if blood 
comes out, it may indicate that a blood 
vessel was perforated.
Puncture of these sites should be avoided, however, if any 
of these substances are present, it is better to remove 
the needle from the animal, evaluate the puncture 
wound, evaluate if the animal requires some treatment 
and, if feasible, redo the puncture. If the syringe got 
contaminated, discard the needle and syringe into the 
sharps bin and biohazard waste bin, respectively, and use 
a new syringe and a new needle in the next injection.
After the intraperitoneal 
injection
Complications may arise that affect the 
well-being of the animal such as bleeding 
at the injection site or even more serious 
ones such as peritonitis, laceration of 
internal organs, and infection.
The animal should be monitored immediately after the 
injection, about 10 minutes later and the next day.
• If bleeding occurs, place gauze and apply pressure. 
Once bleeding stops, clean the site with gauze and 
water.
• In case of peritonitis, laceration of internal organs and 
/ or infection, consult a veterinarian to assess if the 
animal can continue in the experiment.
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Figure 1. Lipopolysaccharide (LPS) (A) location, (B) molecular structure and (C) effects on immune cell signaling. (A) The gram-negative 
bacteria cell envelope is composed of a phospholipid inner membrane, followed by a small periplasmic space with little amounts of 
peptidoglycan cell wall and is topped by an outer membrane which contains the LPS among other structures such as membrane proteins. 
(B) At the molecular level, LPS can be divided in four main parts: the lipid A, made up by fatty acid chains attached to a glucosamine 
disaccharide; an inner and an outer oligosaccharide core; and a final section called O antigen, consisting of a repetitive polysaccharide which 
varies between bacterial species and strains. (C) Upon contact with its corresponding receptor molecules -the CD14-TLR 4-MD-2 system- 
the LPS elicits a signaling cascade within the immune cell (e.g. microglia), which may culminate in the synthesis and/or release of pro- and 
anti-inflammatory cytokines, as well as complement proteins and the inducible nitric oxide synthase. 
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CONCLUSIONS AND OUTLOOK
LPS challenge has been used in animal 
models for decades and even humans as an aid 
to elucidate the pathophysiology of immune 
system-related diseases and affective disorders. 
It is also a tool to investigate the epigenome that 
is controlled by social environment and immune 
system activity (57,58). There are numerous 
data on LPS applications. All tissues/organs 
and systems are affected by LPS. However, the 
dynamics of responses are different; some cell 
signaling systems (e.g., TLRs) respond within 
few minutes, while response of others may 
require hours. 
The range of the applied LPS doses in rats 
reported in literature varies from 0.05 nanograms /
kg to up to 5 mg/kg (60). The doses of administration 
should be optimized for the experiment that will be 
performed. As stated in the introduction, the best 
thing to do is to review the literature and find out 
the exact dose proven to get the effects wanted in 
each aim of the experiments performed.
Our main goal was to provide a guide to 
prepare LPS in saline solution and basic steps on 
how to perform an intraperitoneal injection. Each 
investigator should adapt the protocol according to 
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Figure 2. Injection site. For an adequate intraperitoneal 
injection, the ventral lower right quadrant of the animal is 
the preferred site. If the animal must be injected several 
times, injections may be applied alternating between the left 
and right lower quadrants.
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